Loading
NASDAQHealthcareMedical - Devices
Latest quote
$0.6534
+$0.0022 · +0.34%
Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.
Previous close
$0.6534
+$0.0022 · +0.34%
After-hours
$0.66
+$0.0066 · +1.01%
Oct 7, 5:27 PM ET
Regular session · ET · Market data may be delayed.
Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.
Day range
Current $0.6534
52-week range
Current $0.6534
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
40
Expensive
Sentiment
43
Mixed
Risk
79
High Risk
Momentum
35
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.
Day range
Current $0.6534
52-week range
Current $0.6534
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 241K USD | 225K USD | 316K USD | 237K USD | 310K USD |
| Cost of goods sold | 874K USD | 742K USD | 789K USD | 498K USD | 769K USD |
| Gross profit | −633K USD | −517K USD | −473K USD | −261K USD | −459K USD |
| Research and development | 12.49M USD | 10.18M USD | 8.96M USD | 4.98M USD | 3.94M USD |
| Selling, general, and administrative | 9.15M USD | 8.56M USD | 8.93M USD | 3.47M USD | 2.47M USD |
| Operating expenses | 21.64M USD | 18.74M USD | 17.89M USD | 8.45M USD | 6.41M USD |
| Interest income | — | — | — | — | 37.67K USD |
| Interest expense | 1.59M USD | 816K USD | — | — | — |
| Depreciation and amortization | 302K USD | 173K USD | 133K USD | 75K USD | 71K USD |
| Operating income | −22.27M USD | −19.26M USD | −18.36M USD | −8.71M USD | −6.87M USD |
| Net income | −23.76M USD | −20.8M USD | −29.92M USD | −15.92M USD | −8.68M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$2.00
206.09% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
